A phase I study assessing SLN360 in cardiovascular disorders
Latest Information Update: 24 May 2020
At a glance
- Drugs Zerlasiran (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; First in man
Most Recent Events
- 20 May 2020 According to a Silence Therapeutics media release, in spite of the COVID-19 pandemic, the company still expects to start this trial this year.
- 25 Mar 2020 According to a Silence Therapeutics media release, the company expects to generate interim data from the trial around the middle of 2021.
- 10 Jan 2020 New trial record